Evidence map›Paper›PMID 41836378›Full record

ArticleFrontiers in immunology2026

A 7-gene expression signature predicts immune microenvironment remodeling and neoadjuvant chemo-immunotherapy response in lung squamous cell carcinoma.

Shaoling Li, Junhong Guo, Yan Huang, Zhengwei Dong, Ranyue Wang, Huifang Liu, Yaoqi Xiao, Jin Wang, Xing Li, Zhan Huang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shaoling Li *Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Junhong Guo *Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Yan HuangDepartment of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhengwei DongDepartment of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Ranyue WangDepartment of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Huifang LiuDepartment of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Yaoqi XiaoNanchang University, Nanchang, China.
Jin WangDepartment of Medicine, Amoy Diagnostics Co., Ltd., Xiamen, China.
Xing LiDepartment of Medicine, Amoy Diagnostics Co., Ltd., Xiamen, China.
Zhan HuangDepartment of Medicine, Amoy Diagnostics Co., Ltd., Xiamen, China.
Tao HuDepartment of Medicine, Amoy Diagnostics Co., Ltd., Xiamen, China.
Changbin ZhuDepartment of Medicine, Amoy Diagnostics Co., Ltd., Xiamen, China.
Likun HouDepartment of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Chunyan WuDepartment of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Neoadjuvant chemo-immunotherapy (NCI) has significantly improved outcomes in advanced lung squamous cell carcinoma (LUSC). However, some patients remain resistant to NCI, resulting in poor outcomes. The mechanisms behind this resistance remain unclear. Methods: Forty LUSC patients receiving NCI were selected and categorized into major pathological response (MPR) and non-MPR groups based on their pathological response. Pre- and post-treatment samples underwent bulk RNA sequencing (RNA-seq) to assess the composition of immune cell subtypes, including T cells, B cells, NK cells, dendritic cells, and macrophages. A panel of 134 immune cell subtypes were further analyzed to differentiate between "cold" and "hot" tumor immune phenotypes. Results: After surgery, 75% of patients achieved MPR, while 25% were classified as non-MPR. In MPR patients, NCI transformed the tumor immune microenvironment (TME) from a "cold" to a "hot" phenotype, characterized by increased anti-tumor immune activity. We identified seven genes potentially linked to NCI response. Among these, Conclusions: NCI altered the TME and was linked to treatment response in LUSC. Identifying predictors of immunotherapy efficacy, such as

Indexed as

Carcinoma, Squamous CellLung NeoplasmsTranscriptomeTumor MicroenvironmentAgedBiomarkers, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunotherapyMaleMiddle AgedNeoadjuvant TherapyTreatment OutcomeBiomarkers, TumorHOXC13lung squamous cell carcinomaneoadjuvant chemo-immunotherapyRNA sequencingtumor microenvironment

Identifiers

PMID41836378
PMCPMC12979163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.